Targeted treatment of recurrent platinum-resistant ovarian cancer: Current and emerging therapies

Cancer Management and Research

Volumn 3, Issue 1, 2011, Pages 25-38

  Mantia Smaldone, Gina M ^a   Edwards, Robert P ^b   Vlad, Anda M ^c  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Growth factors; Immunotherapy; Ovarian cancer; Platinum resistant; Targeted therapy

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CYCLOPHOSPHAMIDE; DACLIZUMAB; DENDRITIC CELL VACCINE; DENILEUKIN DIFTITOX; DOCETAXEL; DOXORUBICIN; ERLOTINIB; FARLETUZUMAB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; IXABEPILONE; NAVELBINE; PACLITAXEL; PANITUMUMAB; PLATINUM COMPLEX; QS 21; RAMUCIRUMAB; SORAFENIB; TOPOTECAN; TRABECTEDIN; UNINDEXED DRUG; VANDETANIB; VELIPARIB;

ANGIOGENESIS; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CELL ADHESION; CENTRAL NERVOUS SYSTEM DISEASE; DNA REPAIR; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FOLATE METABOLISM; HAND FOOT SYNDROME; HUMAN; NEPHROTOXICITY; NEUROTOXICITY; OVARY CANCER; OVERALL SURVIVAL; PERITONEUM CANCER; RECURRENT CANCER; REVIEW; TUMOR IMMUNITY; UNSPECIFIED SIDE EFFECT;

EID: 79251471161     PISSN: None     EISSN: 11791322     Source Type: Book Series    
DOI: None     Document Type: Review

References (133)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225-249.
2. Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351(24): 2519-2529.
3. Gadducci A, Landoni F, Maggino T, et al. Serum CA125 assay at the time of relapse has no prognostic relevance in patients undergoing chemotherapy for recurrent ovarian cancer: a multicenter Italian study. Int J Gynecol Cancer. 1997;7(1):78-83.
4. Heintz A P, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006;95(Suppl 1):S161-S192.
5. Thigpen JT, Blessing JA, Ball H, Hummel SJ, Barrett RJ. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J Clin Oncol. 1994;12(9):1748-1753.
6. Ushijima K. Treatment for recurrent ovarian cancer-at frst relapse. J Oncol. 2010:497429.
7. Monk BJ, Coleman RL. Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds. Int J Gynecol Cancer. 2009;19(Suppl 2):S63-S67.
8. Gonzalez-Martin AJ, Calvo E, Bover I, et al. Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study. Ann Oncol. 2005;16(5):749-755.
9. Pfsterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006;24(29): 4699-4707.
10. Alberts DS, Liu PY, Wilczynski S P, et al. Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200). Gynecol Oncol. 2008;108(1):90-94.
11. Spriggs D. Optimal sequencing in the treatment of recurrent ovarian cancer. Gynecol Oncol. 2003;90(3 pt 2):S39-S44.
12. Markman M. Optimal management of recurrent ovarian cancer. Int J Gynecol Cancer. 2009;19(Suppl 2):S40-S43.
13. Herzog TJ. Recurrent ovarian cancer: how important is it to treat to disease progression? Clin Cancer Res. 2004;10(22):7439-7449.
14. Cree IA, Kurbacher CM, Lamont A, Hindley AC, Love S. A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer. Anticancer Drugs. 2007; 18(9):1093-1101.
15. Schrag D, Garewal HS, Burstein HJ, et al. American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol. 2004;22(17):3631-3638.
16. Gordon AN, Granai CO, Rose PG, et al. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol. 2000;18(17):3093-3100.
17. Muggia FM, Hainsworth JD, Jeffers S, et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modifcation by liposomal encapsulation. J Clin Oncol. 1997;15(3):987-993.
18. Monk BJ, Herzog TJ, Kaye SB, et al. Trabectedin plus pegylated lipo-somal Doxorubicin in recurrent ovarian cancer. J Clin Oncol. 2010; 28(19):3107-3114.
19. Havrilesky LJ, Alvarez AA, Sayer RA, et al. Weekly low-dose carbo-platin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer. Gynecol Oncol. 2003;88(1):51-57.
20. Rose PG, Blessing JA, Ball HG, et al. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2003;88(2):130-135.
21. Markman M, Webster K, Zanotti K, et al. Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer. Gynecol Oncol. 2003;90(3):593-596.
22. Mutch DG, Orlando M, Goss T, et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2007;25(19): 2811-2818.
23. Bookman MA, Malmstrom H, Bolis G, et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol. 1998;16(10): 3345-3352.
24. Safra T, Menczer J, Bernstein R, et al. Effcacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer. Gynecol Oncol. 2007;105(1):205-210.
25. Rose PG, Blessing JA, Mayer AR, Homesley HD. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 1998;16(2):405-410.
26. Bodurka DC, Levenback C, Wolf JK, et al. Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer. J Clin Oncol. 2003;21(2):291-297.
27. Sorensen P, Hoyer M, Jakobsen A, et al. Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma. Gynecol Oncol. 2001;81(1):58-62.
28. Markman M, Hakes T, Reichman B, et al. Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease. J Clin Oncol. 1992;10(2):243-248.
29. Prefontaine M, Donovan JT, Powell JL, Buley L. Treatment of refractory ovarian cancer with 5-fuorouracil and leucovorin. Gynecol Oncol. 1996;61(2):249-252.
30. Kowalski RJ, Giannakakou P, Hamel E. Activities of the microtubule-stabilizing agents epothilones A and B with purifed tubulin and in cells resistant to paclitaxel (Taxol(R)). J Biol Chem. 1997;272(4): 2534-2541.
31. De Geest K, Blessing JA, Morris RT, et al. Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study. J Clin Oncol. 28(1):149-153.
32. Carter NJ, Keam SJ. Trabectedin: a review of its use in the management of soft tissue sarcoma and ovarian cancer. Drugs. 2007;67(15): 2257-2276.
33. Krasner CN, McMeekin DS, Chan S, et al. A Phase II study of trabect-edin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br J Cancer. 2007;97(12): 1618-1624.
34. Shih C, Chen VJ, Gossett LS, et al. LY231514, a pyrrolo[2,3-d]-pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. 1997;57(6):1116-11123.
35. Miller DS, Blessing JA, Krasner CN, et al. Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. J Clin Oncol. 2009;27(16):2686-2691.
36. Kamsteeg M, Rutherford T, Sapi E, et al. Phenoxodiol-an isofavone analog-induces apoptosis in chemoresistant ovarian cancer cells. Oncogene. 2003;22(17):2611-2620.
37. Alvero AB, O'Malley D, Brown D, et al. Molecular mechanism of phenoxodiol-induced apoptosis in ovarian carcinoma cells. Cancer. 2006;106(3):599-608.
38. Fracasso PM, Blessing JA, Morgan MA, Sood AK, Hoffman JS. Phase II study of oxaliplatin in platinum-resistant and refractory ovarian cancer: a gynecologic group study. J Clin Oncol. 2003;21(15):2856-2859.
39. Pectasides D, Pectasides M, Farmakis D, et al. Oxaliplatin plus high-dose leucovorin and 5-fuorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: a phase II study. Gynecol Oncol. 2004;95(1):165-172.
40. Faivre S, Kalla S, Cvitkovic E, et al. Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: an investigator-originated compassionate-use experience. Ann Oncol. 1999;10(9):1125-1128.
41. Recchia F, Saggio G, Amiconi G, et al. A multicenter phase II study of pegylated liposomal doxorubicin and oxaliplatin in recurrent ovarian cancer. Gynecol Oncol. 2007;106(1):164-169.
42. Germano D, Rosati G, Manzione L. Gemcitabine combined with oxaliplatin (GEMOX) as salvage treatment in elderly patients with advanced ovarian cancer refractory or resistant to platinum: a single institution experience. J Chemother. 2007;19(5):577-581.
43. Wosikowski K, Lamphere L, Unteregger G, et al. Preclinical antitumor activity of the oral platinum analog satraplatin. Cancer Chemother Pharmacol. 2007;60(4):589-600.
44. Steinman RM. Dendritic cells: understanding immunogenicity. Eur J Immunol. 2007;37(Suppl 1):S53-S60.
45. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348(3):203-213.
46. Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8+ tumor-infltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A. 2005;102(51):18538-18543.
47. Curiel TJ, Coukos G, Zou L, et al. Specifc recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10(9):942-949.
48. Liu B, Nash J, Runowicz C, et al. Ovarian cancer immunotherapy: opportunities, progresses and challenges. J Hematol Oncol. 2010;3:7.
49. Cheever MA, Allison J P, Ferris AS, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009;15(17):5323-5337.
50. Hird V, Maraveyas A, Snook D, et al. Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br J Cancer. 1993;68(2): 403-406.
51. Nicholson S, Bomphray CC, Thomas H, et al. A phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer. Cancer Immunol Immunother. 2004;53(9):809-816.
52. Oei AL, Verheijen RH, Seiden M V, et al. Decreased intraperitoneal disease recurrence in epithelial ovarian cancer patients receiving intraperitoneal consolidation treatment with yttrium-90-labeled murine HMFG1 without improvement in overall survival. Int J Cancer. 2007; 120(12):2710-2714.
53. Ehlen TG, Hoskins PJ, Miller D, et al. A pilot phase 2 study of oregov-omab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer. Int J Gynecol Cancer. 2005;15(6): 1023-1034.
54. Gordon AN, Schultes BC, Gallion H, et al. CA125- and tumor-specifc T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients. Gynecol Oncol. 2004;94(2): 340-351.
55. Pfsterer J, du Bois A, Sehouli J, et al. The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR. Ann Oncol. 2006;17(10):1568-1577.
56. Reinartz S, Kohler S, Schlebusch H, et al. Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II). Clin Cancer Res. 2004;10(5):1580-1587.
57. Sabbatini P, Dupont J, Aghajanian C, et al. Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clin Cancer Res. 2006;12(18):5503-5510.
58. Connor J, Bannerji R, Saito S, et al. Regression of bladder tumors in mice treated with interleukin 2 gene-modifed tumor cells. J Exp Med. 1993;177(4):1127-1134.
59. Vlad AM, Budiu RA, Lenzner DE, et al. A phase II trial of intraperi-toneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancer. Cancer Immunol Immunother. 2009. [Epub ahead of print].
60. Roche MR, Rudd PJ, Krasner CN, et al. Phase II trial of GM-CSF in women with asymptomatic recurrent mullerian tumors. Gynecol Oncol. 2010;116(2):168-172.
61. Schmeler KM, Vadhan-Raj S, Ramirez PT, et al. A phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer. Gynecol Oncol. 2009;113(2):210-215.
62. Kaur T, Slavcev RA, Wettig SD. Addressing the challenge: current and future directions in ovarian cancer therapy. Curr Gene Ther. 2009;9(6):434-458.
63. Qian HN, Liu GZ, Cao SJ, Feng J, Ye X. The experimental study of ovarian carcinoma vaccine modifed by human B7-1 and IFN-gamma genes. Int J Gynecol Cancer. 2002;12(1):80-85.
64. Kantoff P W, Higano CS, Shore ND, et al; IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411-422.
65. Cannon MJ, O'Brien TJ. Cellular immunotherapy for ovarian cancer. Expert Opin Biol Ther. 2009;9(6):677-88.
66. Brossart P, Wirths S, Stuhler G, et al. Induction of cytotoxic T- lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood. 2000;96(9):3102-3108.
67. Hernando JJ, Park T W, Kubler K, et al. Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial. Cancer Immunol Immunother. 2002;51(1):45-52.
68. Rosenberg SA, Restifo N P, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immuno-therapy. Nat Rev Cancer. 2008;8(4):299-308.
69. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23(10):2346-2357.
70. Aoki Y, Takakuwa K, Kodama S, et al. Use of adoptive transfer of tumor-infltrating lymphocytes alone or in combination with cisplatin-containing chemotherapy in patients with epithelial ovarian cancer. Cancer Res. 1991;51(7):1934-1939.
71. Carpenito C, Milone MC, Hassan R, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A. 2009;106(9): 3360-3365.
72. Kershaw MH, Westwood JA, Parker LL, et al. A phase I study on adoptive immunotherapy using gene-modifed T cells for ovarian cancer. Clin Cancer Res. 2006;12(20 pt 1):6106-6115.
73. Hodi FS, Butler M, Oble DA, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A. 2008;105(8):3005-3010.
74. Barnett B, Kryczek I, Cheng P, Zou W, Curiel TJ. Regulatory T cells in ovarian cancer: biology and therapeutic potential. Am J Reprod Immunol. 2005;54(6):369-377.
75. Markman M. Antiangiogenic drugs in ovarian cancer. Expert Opin Pharmacother. 2009;10(14):2269-2277.
76. Abu-Jawdeh GM, Faix JD, Niloff J, et al. Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. Lab Invest. 1996; 74(6):1105-1115.
77. Cooper BC, Ritchie JM, Broghammer CL, et al. Preoperative serum vascular endothelial growth factor levels: signifcance in ovarian cancer. Clin Cancer Res. 2002;8(10):3193-3197.
78. Raspollini MR, Amunni G, Villanucci A, et al. Prognostic signifcance of microvessel density and vascular endothelial growth factor expression in advanced ovarian serous carcinoma. Int J Gynecol Cancer. 2004; 14(5):815-823.
79. Burger RA, Sill M W, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25(33):5165-5171.
80. Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007;25(33): 5180-5186.
81. Cheng X, Moroney J W, Levenback CF, et al. What is the beneft of bevacizumab combined with chemotherapy in patients with recurrent ovarian, fallopian tube or primary peritoneal malignancies? J Chemother. 2009;21(5):566-572.
82. Garcia AA, Hirte H, Fleming G, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol. 2008; 26(1):76-82.
83. Camidge DR, Eckhardt SG, Diab S, et al. A phase I dose-escalation study of weekly IMC-1121B. a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR2) IgG1 monoclonal antibody (Mab), in patients (pts) with advanced cancer. J Clin Oncol. 2006;24(185 (June 20 Suppl)):3032.
84. A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma. Accessed 2010 Aug 11. http://clinicaltrials.gov/ct2/show/NCT00721162.
85. Ledermann JA, Raja FA. Targeted trials in ovarian cancer. Gynecol Oncol. 2010;119(1):151-156.
86. Tew W, Colombo N, Ray-Caquard I, et al. VEGF-Trap for patients with recurrent platinum resistant epithelial ovarian cancer. J Clin Oncol. 2008;25(18S):Abstract 14598.
87. Wedge SR, Kendrew J, Hennequin L F, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 2005; 65(10):4389-4400.
88. Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer. 2002;94(5):1593-1611.
89. Lafky JM, Wilken JA, Baron AT, Maihle NJ. Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. Biochim Biophys Acta. 2008;1785(2): 232-265.
90. Schilder RJ, Pathak HB, Lokshin AE, et al. Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. Gynecol Oncol. 2009;113(1):21-27.
91. Wu M, Rivkin A, Pham T. Panitumumab: human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer. Clin Ther. 2008;30(1):14-30.
92. Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastu-zumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2007;369(9555):29-36.
93. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/ neu proto-oncogene in human breast and ovarian cancer. Science. 1989; 244(4905):707-712.
94. Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol. 2003;21(2):283-290.
95. Makhija S, Amler LC, Glenn D, et al. Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. J Clin Oncol. 28(7): 1215-1223.
96. Schilder RJ, Sill M W, Chen X, et al. Phase II study of geftinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin Cancer Res. 2005;11(15):5539-5548.
97. Posadas EM, Liel MS, Kwitkowski V, et al. A phase II and pharma-codynamic study of geftinib in patients with refractory or recurrent epithelial ovarian cancer. Cancer. 2007;109(7):1323-1330.
98. Hirte H, Oza A, Swenerton K, et al. A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149). Gynecol Oncol. 118(3):308-312.
99. Apte SM, Bucana CD, Killion JJ, Gershenson DM, Fidler IJ. Expression of platelet-derived growth factor and activated receptor in clinical specimens of epithelial ovarian cancer and ovarian carcinoma cell lines. Gynecol Oncol. 2004;93(1):78-86.
100. Schilder RJ, Sill M W, Lee RB, et al. Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2008;26(20):3418-3425.
101. Coleman RL, Broaddus RR, Bodurka DC, et al. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers. Gynecol Oncol. 2006;101(1):126-131.
102. Biagi JJ, Oza AM, Chalchal HI, et al. A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study. Ann Oncol. 2010. [Epub ahead of print].
103. Friedlander M, Hancock KC, Rischin D, et al. A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol. 2010;119(1):32-37.
104. Kalli KR. MORAb-003, a fully humanized monoclonal antibody against the folate receptor alpha, for the potential treatment of epithelial ovarian cancer. Curr Opin Investig Drugs. 2007;8(12):1067-1073.
105. Weitman SD, Lark RH, Coney LR, et al. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res. 1992;52(12):3396-3401.
106. Chung MK, Han SS, Roh JK. Synergistic embryotoxicity of combination pyrimethamine and folic acid in rats. Reprod Toxicol. 1993;7(5): 463-468.
107. Molthoff CF, Prinssen HM, Kenemans P, et al. Escalating protein doses of chimeric monoclonal antibody MOv18 immunoglobulin G in ovarian carcinoma patients: a phase I study. Cancer. 1997;80 (Suppl 12):2712-2720.
108. Van Zanten-Przybysz I, Molthoff C, Gebbinck JK, et al. Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot study. J Cancer Res Clin Oncol. 2002;128(9):484-492.
109. Coliva A, Zacchetti A, Luison E, et al. 90Y Labeling of monoclonal antibody MOv18 and preclinical validation for radioimmunotherapy of human ovarian carcinomas. Cancer Immunol Immunother. 2005; 54(12):1200-1213.
110. Zacchetti A, Coliva A, Luison E, et al. (177)Lu- labeled MOv18 as compared to (131)I- or (90)Y-labeled MOv18 has the better therapeutic effect in eradication of alpha folate receptor-expressing tumor xenografts. Nucl Med Biol. 2009;36(7):759-770.
111. Ebel W, Routhier EL, Foley B, et al. Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha. Cancer Immun. 2007;7:6.
112. Ahmed S, Gerst S, Vander Els N, Pezzuli S, Sabbatini P, Hensley M, Dupont J, et al. Phase I Study of MORAb-003, a humanized anti-folate receptor-alpha, monoclonal antibody, in platinum resistant ovarian cancer. Proc Am Soc Clin Oncol. 2006;25:Abstract # 5027.
113. Philips M, Armstrong D, Coleman R, et al. Novel phase II study design of MORAb-003, a monoclonal antibody against folate receptor alpha in platinum-sensitive ovarian cancer in frst relapse. Proc Am Soc Clinc Oncol. 2007;43:Abstract # 5583.
114. Went PT, Lugli A, Meier S, et al. Frequent EpCam protein expression in human carcinomas. Hum Pathol. 2004;35(1):122-128.
115. Bellone S, Siegel ER, Cocco E, et al. Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/ chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specifc immunotherapy. Int J Gynecol Cancer. 2009;19(5):860-866.
116. Ruf P, Lindhofer H. Induction of a long-lasting antitumor immunity by a trifunctional bispecifc antibody. Blood. 2001;98(8):2526-2534.
117. Heiss MM, Murawa P, Koralewski P, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. Int J Cancer. 2010;127(9):2209-2221.
118. Hassan R, Bullock S, Premkumar A, et al. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res. 2007;13(17):5144-5149.
119. Oral contraceptive use and the risk of ovarian cancer. The Centers for Disease Control Cancer and Steroid Hormone Study. JAMA. 1983; 249(12):1596-1599.
120. O'Donnell AJ, Macleod KG, Burns DJ, Smyth JF, Langdon S P. Estrogen receptor-alpha mediates gene expression changes and growth response in ovarian cancer cells exposed to estrogen. Endocr Relat Cancer. 2005;12(4):851-866.
121. Williams CJ. Tamoxifen for relapse of ovarian cancer. Cochrane Database Syst Rev. 2001(1):CD001034.
122. Ramirez PT, Schmeler KM, Milam MR, et al. Effcacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum. Gynecol Oncol. 2008;110(1): 56-59.
123. Smyth JF, Gourley C, Walker G, et al. Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients. Clin Cancer Res. 2007;13(12):3617-3622.
124. Argenta PA, Thomas SG, Judson PL, et al. A phase II study of fulves-trant in the treatment of multiply-recurrent epithelial ovarian cancer. Gynecol Oncol. 2009;113(2):205-209.
125. Rocereto TF, Brady WE, Shahin MS, et al. A phase II evaluation of mifepristone in the treatment of recurrent or persistent epithelial ovarian, fallopian or primary peritoneal cancer: a gynecologic oncology group study. Gynecol Oncol. 2010;16(3):332-334.
126. Balbi G, Piano LD, Cardone A, Cirelli G. Second-line therapy of advanced ovarian cancer with GnRH analogs. Int J Gynecol Cancer. 2004;14(5):799-803.
127. Hasan J, Ton N, Mullamitha S, et al. Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer. Br J Cancer. 2005; 93(6):647-651.
128. Verschraegen C F, Westphalen S, Hu W, et al. Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer. Gynecol Oncol. 2003;90(3): 552-559.
129. D'Andrea AD, Grompe M. The Fanconi anaemia/BRCA pathway. Nat Rev Cancer. 2003;3(1):23-34.
130. Pal T, Permuth-Wey J, Betts JA, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer. 2005;104(12):2807-2816.
131. McCabe N, Turner NC, Lord CJ, et al. Defciency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP- ribose) polymerase inhibition. Cancer Res. 2006;66(16): 8109-8115.
132. Konstantinopoulos PA, Spentzos D, Karlan BY, et al. Gene expression profle of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol. 2010;28(22):3555-3561.
133. Audeh M W, Carmichael J, Penson RT, et al. Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010;376(9737):245-251.